Fibroblast Growth Factor Receptor Inhibitor–Associated Retinopathy

Erdafitinib received accelerated approval from the US Food and Drug Administration in April 2019 after a phase 2 trial for locally advanced or metastatic urothelial carcinoma.¹ It works as a tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) 1 to 4 (pan-FGFR inhibitor) and is the first FGFR kinase inhibitor approved by the US Food and Drug Administration.¹ Retinal findings were noted in the phase 2 trial.